| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1016/0272-6386(95)90568-5 |
| P698 | PubMed publication ID | 7771482 |
| P2093 | author name string | Jennette JC | |
| Falk RJ | |||
| Hogan SL | |||
| Muller KE | |||
| P433 | issue | 6 | |
| P304 | page(s) | 862-875 | |
| P577 | publication date | 1995-06-01 | |
| P1433 | published in | American Journal of Kidney Diseases | Q4744250 |
| P1476 | title | A review of therapeutic studies of idiopathic membranous glomerulopathy | |
| P478 | volume | 25 |
| Q41541011 | A 10-year follow-up of idiopathic membranous nephropathy patients on steroids and cyclophosphamide: a case series |
| Q43119261 | A Case of Concurrent MPO-/PR3-Negative ANCA-Associated Glomerulonephritis and Membranous Glomerulopathy |
| Q38783739 | A case presenting with the possible relationship between myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis and membranous changes of the glomerular basement membrane |
| Q40054212 | A comprehensive narrative review of diagnostic biomarkers in human primary membranous nephropathy. |
| Q43805473 | A rare complication of idiopathic membranous nephropathy: crescentic transformation |
| Q38562318 | A review of the re-emergence of adrenocorticotrophic hormone therapy in glomerular disease, more than a drug of last resort? |
| Q33622282 | An adult case of severe steroid-resistant Henoch-Schönlein purpura nephritis treated with intravenous cyclophosphamide and tonsillectomy |
| Q36524378 | Analysis of the prognostic risk factors of idiopathic membranous nephropathy using a new surrogate end-point |
| Q42871508 | Application of artificial neural networks in estimating predictive factors and therapeutic efficacy in idiopathic membranous nephropathy |
| Q87393375 | Chapter 7: Idiopathic membranous nephropathy |
| Q43058602 | Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy |
| Q36314982 | Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy |
| Q34248343 | Controversies in the treatment of idiopathic membranous nephropathy |
| Q34074851 | Cyclosporin treatment of glomerular diseases |
| Q37516426 | Effect of steroid and cyclosporine in membranous nephropathy that is resistant to steroid and/or cytotoxic treatment |
| Q44420378 | Efficacy of mizoribine followed by low-dose prednisone in patients with idiopathic membranous nephropathy and nephrotic-range proteinuria |
| Q35641499 | Evidence-based guide to slowing the progression of early renal insufficiency |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q53706807 | Glucocorticoids in the Treatment of Glomerular Diseases: Pitfalls and Pearls. |
| Q41337284 | Idiopathic membranous nephropathy in the elderly: a comparative study |
| Q37543422 | Idiopathic membranous nephropathy: management strategies |
| Q38027890 | Immunopathological events initiated and maintained by pathogenic IgG autoantibodies in an experimental autoimmune kidney disease |
| Q36810470 | Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials |
| Q24193098 | Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome |
| Q24246172 | Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome |
| Q24248134 | Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome |
| Q100697445 | Kidney transplantation for primary glomerulonephritis: Recurrence risk and graft outcomes with related versus unrelated donors |
| Q37013035 | Latest treatment strategies for membranous nephropathy. |
| Q40663445 | Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. |
| Q26740481 | Management of Membranous Nephropathy in Asia |
| Q37779802 | Management of idiopathic membranous nephropathy |
| Q34117792 | Melanocortin 1 receptor agonists reduce proteinuria |
| Q36167127 | Membranous Nephropathy: Quantifying Remission Duration on Outcome |
| Q37087861 | Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. |
| Q33920367 | Membranous nephropathy in children: clinical presentation and therapeutic approach |
| Q33823525 | Membranous nephropathy: a retrospective observational study of membranous nephropathy in north east and central London. |
| Q44623298 | Membran�se Glomerulonephritis |
| Q33187621 | Mycophenolate mofetil and cyclosporine therapy in membranous nephropathy |
| Q42290044 | Partial remission by cyclosporine monotherapy in a patient with membranous nephropathy superimposed diabetic nephropathy |
| Q40882334 | Patients with primary membranous nephropathy are at high risk of cardiovascular events. |
| Q41854722 | Rapamycin ameliorates proteinuria and restores nephrin and podocin expression in experimental membranous nephropathy. |
| Q36179760 | Recent developments in the management of membranous nephropathy |
| Q57945954 | References |
| Q38072388 | Regaining tolerance to a self-antigen by the modified vaccination technique |
| Q37412829 | Rituximab therapy for membranous nephropathy: a systematic review |
| Q91733769 | Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial |
| Q43087627 | Role of anti-phospholipase A(2) receptor antibodies in the differential diagnosis of diabetic and membranous nephropathy |
| Q35840057 | Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study |
| Q36861628 | Tacrolimus in the treatment of idiopathic nephrotic syndrome. |
| Q38270202 | The Effects of Helicobacter pylori Eradication on Proteinuria in Patients with Primary Glomerulonephritis. |
| Q52985913 | Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events. |
| Q92030146 | Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN) |
| Q80031217 | Treatment aspects of primary nephrotic syndrome in adults |
| Q34097222 | Treatment of idiopathic membranous nephropathy (IMN). |
| Q47850601 | Treatment of primary membranous nephropathy: where are we now? |
| Q45351919 | What is the role of rituximab in idiopathic membranous nephropathy? |
Search more.